10-Q: Penumbra Q1 2026 Earnings: Revenue Up 15.6%, Merger with Boston Scientific Pending

Penumbra, Inc. reported a 15.6% increase in revenue for the first quarter of 2026, driven by strong performance in thrombectomy and embolization products, while preparing for its acquisition by Boston Scientific.

Summary

• Penumbra, Inc. reported first-quarter 2026 revenue of $374.8 million, a 15.6% increase compared to $324.1 million in the same period last year.
• Thrombectomy product revenue grew 12.1% to $253.9 million, while embolization and access product revenue increased by 23.8% to $120.8 million.
• Gross margin improved to 67.6% from 66.6% due to a favorable product mix.
• Operating expenses increased by 25.6% to $192.8 million, primarily due to higher personnel costs and acquisition-related expenses.
• Net income decreased to $32.6 million from $39.2 million in the prior year's quarter.
• The company is proceeding with its acquisition by Boston Scientific, valued at approximately $14.5 billion, with an expected closing by the end of 2026.
• Cash and cash equivalents increased to $241.3 million, and the company has $100 million remaining under its share repurchase authorization.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth and improved gross margins, despite a decrease in net income, with the pending acquisition by Boston Scientific providing a significant positive catalyst.

Positives

• Revenue increased by 15.6% to $374.8 million, driven by strong sales in both thrombectomy and embolization/access product lines.
• Gross margin improved by 1.0 percentage point to 67.6% due to a favorable product mix.
• International revenue saw a notable increase of 16.5% to $78.4 million.
• Net cash provided by operating activities significantly increased to $87.0 million from $49.0 million in the prior year.
• Cash and cash equivalents increased to $241.3 million from $186.9 million at the end of the previous year.

Negatives

• Net income decreased by 16.9% to $32.6 million compared to $39.2 million in the prior year's quarter.
• Diluted earnings per share decreased to $0.82 from $1.00 in the prior year's quarter.
• Sales, General, and Administrative (SG&A) expenses increased significantly by 25.6%, outpacing revenue growth.
• The effective tax rate more than doubled to 21.8% from 10.6% due to a decrease in excess tax benefits from stock-based compensation.

Risks

• The company is subject to intense competition from large, well-capitalized companies.
• The success of new product introductions and the transition from existing products are critical.
• The availability and levels of reimbursement for procedures using its products could impact sales.
• Fluctuations in foreign currency exchange rates can impact international sales revenue.
• The pending acquisition by Boston Scientific introduces integration risks and potential disruptions.
• The company's ability to continue to grow its salesforce and ensure new hires become effective quickly is a factor.

Future Outlook

The company expects to continue developing and building its product portfolio, including thrombectomy, embolization, and access technologies. The acquisition by Boston Scientific is expected to be completed by the end of 2026, subject to customary closing conditions.

Management Comments

• Penumbra, the worlds leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia.
• We believe that the cost-effectiveness of our products is attractive to our customers.
• We expect to continue to develop and build our portfolio of products, including our thrombectomy, embolization, and access technologies, while iterating on our currently available products.

Industry Context

StockSavvy.ai notes that Penumbra's performance aligns with the broader medical device sector's focus on innovation in minimally invasive procedures. The pending acquisition by Boston Scientific highlights ongoing consolidation trends within the industry, driven by the pursuit of specialized technologies and market expansion.

Legal Proceedings

• A former contractor filed a class action and PAGA lawsuit alleging various claims related to wages, overtime, and breaks, which was settled for $4.6 million in March 2025.

Stakeholder Impact

• Shareholders: The pending acquisition by Boston Scientific at $374 per share offers a significant premium and a choice between cash or stock consideration.
• Employees: Stock-based compensation expenses continue to be a significant factor. The acquisition may lead to changes in employment terms or opportunities.
• Customers: Continued innovation and product development are expected to benefit healthcare providers and patients.
• Suppliers: Increased production and potential integration with Boston Scientific may impact supply chain relationships.

Next Steps

• Complete the acquisition by Boston Scientific, subject to shareholder and regulatory approvals.
• Continue to develop and introduce new products.
• Expand manufacturing operations, including the facility in Costa Rica.
• Continue to invest in research and development activities.

Key Dates

Recommendation

The pending acquisition by Boston Scientific at a premium price ($374 per share) provides a clear valuation floor and upside potential. While the company's operational performance is strong with significant revenue growth, the uncertainty surrounding the closing of the merger and the choice of consideration (cash vs. stock) warrants a 'hold' recommendation until the transaction is finalized. Investors should monitor the progress of regulatory approvals and shareholder votes.

Keywords

Penumbra, 10-Q, Medical Devices, Thrombectomy, Embolization, Boston Scientific, Merger, Q1 Earnings